|By PR Newswire||
|January 29, 2014 07:16 PM EST||
KANSAS CITY, Kan., Jan. 29, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the full exercise of the underwriters' option to purchase 975,000 additional shares of common stock in connection with the company's previously announced public offering of 6,500,000 shares of common stock. The additional shares are comprised of 150,000 shares of common stock being sold by Aratana and 825,000 shares of common stock being sold by a selling stockholder. With the exercise of the underwriters' option, gross proceeds to Aratana from the offering are expected to be $97.85 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics.
Jefferies LLC, Barclays, and William Blair are acting as joint book-running managers for the offering. JMP Securities and Craig-Hallum Capital Group are acting as co-managers.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.
The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus related to the offering may be obtained, when available, from Jefferies LLC, c/o Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th FL, New York, NY 10022, [email protected], (877) 547-6340; or Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, [email protected], (888) 603-5847; or William Blair, Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, [email protected], telephone: (800) 621-0687.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
[email protected]; (212) 375-2664
[email protected]; (212) 375-2694
SOURCE Aratana Therapeutics, Inc.
While DevOps promises a better and tighter integration among an organization’s development and operation teams and transforms an application life cycle into a continual deployment, Chef and Azure together provides a speedy, cost-effective and highly scalable vehicle for realizing the business values of this transformation. In his session at @DevOpsSummit at 19th Cloud Expo, Yung Chou, a Technology Evangelist at Microsoft, will present a unique opportunity to witness how Chef and Azure work tog...
Oct. 1, 2016 06:30 AM EDT Reads: 1,913
Oct. 1, 2016 06:15 AM EDT Reads: 793
Oct. 1, 2016 06:00 AM EDT Reads: 2,794
Oct. 1, 2016 06:00 AM EDT Reads: 1,935
Oct. 1, 2016 05:45 AM EDT Reads: 1,335
Oct. 1, 2016 05:30 AM EDT Reads: 631
Oct. 1, 2016 05:15 AM EDT Reads: 1,434
Oct. 1, 2016 05:00 AM EDT Reads: 4,752
Oct. 1, 2016 04:45 AM EDT Reads: 571
Oct. 1, 2016 04:30 AM EDT Reads: 1,812
Oct. 1, 2016 04:00 AM EDT Reads: 5,479
Oct. 1, 2016 04:00 AM EDT Reads: 3,127
Oct. 1, 2016 04:00 AM EDT Reads: 1,657
Oct. 1, 2016 03:30 AM EDT Reads: 1,232
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Oct. 1, 2016 03:00 AM EDT Reads: 2,454